Business Description
EVE Health Group Ltd
ISIN : AU000000EVE3
Total Employee Number:
3Compare
Compare
Traded in other countries / regions
EVE.Australia IPO Date
2004-04-08Description
EVE Health Group Ltd operates the Meluka Australia business and the continued development and commercialization of regulated pharmaceutical products. It progressed the commercialization of its two pharmaceutical products, Dyspro and Libbo, with particular emphasis on solubility-enhanced drug delivery technologies and evidence based formulations targeting sexual health, women's health, and related therapeutic areas. Dyspro commenced commercial distribution and was prescribed to its first patients during the year. Libbo completed initial production and was launched alongside the activation of the Group's men's health platform. Its segments are Meluka (branded wellness consumer products) and Nextract (pharmaceutical products and intellectual property).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 31.74 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.46 | |||||
Beneish M-Score | -1.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -39.4 | |||||
3-Year EBITDA Growth Rate | 29.3 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
3-Year FCF Growth Rate | 22.7 | |||||
3-Year Book Growth Rate | -29.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.42 | |||||
9-Day RSI | 61.86 | |||||
14-Day RSI | 57.13 | |||||
3-1 Month Momentum % | -27.27 | |||||
6-1 Month Momentum % | -23.81 | |||||
12-1 Month Momentum % | -38.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.28 | |||||
Quick Ratio | 3.95 | |||||
Cash Ratio | 3.75 | |||||
Days Inventory | 76.89 | |||||
Days Sales Outstanding | 15.41 | |||||
Days Payable | 152.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.8 | |||||
Shareholder Yield % | -34.85 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.79 | |||||
Operating Margin % | -164.79 | |||||
Net Margin % | -163.92 | |||||
EBITDA Margin % | -152.13 | |||||
FCF Margin % | -151.26 | |||||
OCF Margin % | -151.08 | |||||
ROE % | -50.36 | |||||
ROA % | -45.47 | |||||
ROIC % | -63.43 | |||||
3-Year ROIIC % | -28.88 | |||||
ROC (Joel Greenblatt) % | -125866.67 | |||||
ROCE % | -50.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.25 | |||||
PB Ratio | 1.55 | |||||
EV-to-EBIT | -2.7 | |||||
EV-to-EBITDA | -2.91 | |||||
EV-to-Revenue | 4.42 | |||||
EV-to-FCF | -2.92 | |||||
Price-to-GF-Value | 1.7 | |||||
Earnings Yield (Greenblatt) % | -37.04 | |||||
FCF Yield % | -29.12 |
EVE Health Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EVE Health Group Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.025:1 Stock Split | 2025-06-02 | 0.04 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers